For decades, the cannabis industry has claimed that weed could replace opioids for pain management. Now there’s rigorous clinical data to back it up — and the numbers aren’t even close.
German pharmaceutical company Vertanical has released results from its Phase 3 clinical program for VER-01, a full-spectrum cannabis extract designed to treat chronic low back pain. The results, drawn from over 1,300 patients across 66 trial sites in Germany and Austria, show that VER-01 relieved pain up to twice as effectively as opioids over a 12-month treatment period.
That’s not a preliminary finding from a small pilot study. That’s the largest rigorous clinical trial of a whole-plant cannabis medicine ever conducted.
What Is VER-01?
VER-01 isn’t the kind of product you’d find at a dispensary. It’s a standardized, pharmaceutical-grade full-spectrum cannabis extract — meaning it contains the full range of cannabinoids, terpenes, and other compounds found in the cannabis plant, but manufactured to pharmaceutical consistency standards.
Vertanical spent seven years and over $250 million developing the drug, which is designed to be prescribed by doctors and dispensed by pharmacists — not sold at a dispensary counter. The company’s approach treats cannabis as what it is: a plant with medicinal compounds that can be refined into a reliable, doseable medicine.
The Trial Results
The two Phase 3 trials measured VER-01 against both placebo and standard opioid therapy. The key findings:
- Pain relief: VER-01 patients reported significantly greater pain reduction than opioid patients over 12 months
- Sleep improvement: Cannabis-treated patients slept better — a common struggle for chronic pain patients
- No dependence: Unlike opioids, VER-01 showed no signs of physical dependence or withdrawal symptoms
- No opioid side effects: Patients didn’t experience constipation, cognitive dulling, or respiratory depression — the trifecta of opioid problems that drive non-compliance
- Sustained efficacy: Pain relief didn’t diminish over time, unlike opioids where tolerance often forces dose escalation
The Opioid Context
The significance of these results can’t be separated from the ongoing opioid crisis. Over 80,000 Americans died from opioid overdoses in 2024. Millions more live with opioid dependence that began with a legitimate pain prescription. The medical establishment has spent years searching for non-opioid alternatives for chronic pain, with limited success.
VER-01 isn’t a theoretical replacement. It’s a tested one — with data from the kind of large-scale, multi-site trials that regulators actually trust.
What Happens Next
VER-01 is expected to launch in Germany in 2026, with European rollout facilitated by EU mutual recognition agreements. Vertanical has announced plans for a U.S. Phase 3 trial to pursue FDA approval, which could make it the first whole-plant cannabis medicine to reach American pharmacies.
If approved by the FDA, VER-01 wouldn’t just be another option in the pain management toolkit. It would be the first cannabis-derived medicine that directly competed with — and potentially replaced — opioids as a front-line chronic pain treatment.
The implications extend beyond pain management. FDA approval of a full-spectrum cannabis extract would fundamentally change how the federal government, insurance companies, and the medical establishment view cannabis as medicine. It would move the conversation from “should cannabis be legal?” to “which cannabis formulation should your doctor prescribe?”
The Bigger Picture
VER-01 is part of an accelerating wave of cannabis clinical research. Over 70 peer-reviewed cannabis studies have already been published in 2026, covering everything from sleep disorders to cancer to diabetes. USDA researchers recently discovered new cancer-research applications in industrial hemp roots. A Springer Nature paper identified hemp-derived nanoparticles as a frontier in nanomedicine.
The era of “we need more research” is ending. The research is here. The question is whether the regulatory framework can keep up.